Jennifer M Trujillo

List of Publications by Year
in descending order

32 papers	1,032 citations	623574 14 h-index	454834 30 g-index
32 all docs	32 docs citations	32 times ranked	1253 citing authors

#	Article	IF	Citations
1	GLP-1 receptor agonists: a review of head-to-head clinical studies. Therapeutic Advances in Endocrinology and Metabolism, 2015, 6, 19-28.	1.4	237
2	Improving Care Transitions: Current Practice and Future Opportunities for Pharmacists. Pharmacotherapy, 2012, 32, e326-37.	1.2	134
3	GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882199732.	1.4	116
4	GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents. Pharmacotherapy, 2014, 34, 1174-1186.	1.2	78
5	Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline. Annals of Internal Medicine, 2020, 173, 813-821.	2.0	60
6	Albiglutide. Annals of Pharmacotherapy, 2014, 48, 1494-1501.	0.9	53
7	Safety and tolerability of onceâ€weekly GLPâ€1 receptor agonists in type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 43-60.	0.7	47
8	Oral semaglutide in type 2 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107520.	1.2	39
9	Improving glycemic control in medical inpatients: A pilot study. Journal of Hospital Medicine, 2008, 3, 55-63.	0.7	35
10	Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes. Pharmacotherapy, 2017, 37, 481-491.	1.2	34
11	Development of a Peer Teaching-Assessment Program and a Peer Observation and Evaluation Tool. American Journal of Pharmaceutical Education, 2008, 72, 147.	0.7	27
12	Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness. Therapeutic Advances in Chronic Disease, 2016, 7, 4-17.	1.1	24
13	A Nutrition Journal and Diabetes Shopping Experience to Improve Pharmacy Students' Empathy and Cultural Competence. American Journal of Pharmaceutical Education, 2009, 73, 37.	0.7	17
14	Low incidence of gastrointestinal adverse events over time with a fixedâ€ratio combination of insulin glargine and lixisenatide versus lixisenatide alone. Diabetes, Obesity and Metabolism, 2018, 20, 2690-2694.	2.2	16
15	Lixisenatide, a Onceâ€Daily Prandial Glucagonâ€Like Peptideâ€1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes. Pharmacotherapy, 2017, 37, 927-943.	1.2	15
16	A Drug Interactions Elective Course. American Journal of Pharmaceutical Education, 2009, 73, 72.	0.7	13
17	Anticipatory guidance in type 2 diabetes to improve disease management; next steps after basal insulin. Postgraduate Medicine, 2018, 130, 365-374.	0.9	12
18	Impact of Student- Versus Instructor-Directed Case Discussions on Student Performance in a Pharmacotherapy Capstone Course. American Journal of Pharmaceutical Education, 2014, 78, 56.	0.7	11

#	Article	IF	Citations
19	Appropriate Titration of Basal Insulin in Type 2 Diabetes and the Potential Role of the Pharmacist. Advances in Therapy, 2019, 36, 1031-1051.	1.3	10
20	Advances in the treatment of type 2 diabetes: impact of dulaglutide. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2016, 9, 125.	1.1	9
21	Cardiovascular Outcomes of New Medications for Type 2 Diabetes. Diabetes Technology and Therapeutics, 2016, 18, 749-758.	2.4	7
22	Effects of Diabetes Numeracy on Glycemic Control and Diabetes Self-Management Behaviors in Patients on Insulin Pump Therapy. Diabetes Therapy, 2019, 10, 1337-1346.	1.2	7
23	Switching basal insulins in type 2 diabetes: practical recommendations for health care providers. Postgraduate Medicine, 2018, 130, 229-238.	0.9	6
24	Initial Management of Severe Hyperglycemia in Patients with Type 2 Diabetes: an Observational Study. Diabetes Therapy, 2013, 4, 375-384.	1.2	5
25	Comparison of Usability, Accuracy, Preference, and Satisfaction Among Three Once-Weekly GLP-1 Receptor Agonist Pen Devices. Diabetes Spectrum, 2018, 31, 359-366.	0.4	5
26	Clinical review and role of clinical pharmacists in obesity management: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 1469-1484.	0.5	4
27	Understanding who you are and how you work: the role of self-assessment. Currents in Pharmacy Teaching and Learning, 2009, 1, 10-16.	0.4	3
28	5-alpha-dihydrotestosterone elevations associated with phentermine use. Therapeutic Advances in Endocrinology and Metabolism, 2018, 9, 255-258.	1.4	3
29	Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300) Tj ETQq1 1 0.784314 rgBT /Over Pharmacy, 2022, , 1-12.	0.5	3
30	Role of combination therapy or coformulation products in treatment of type 2 diabetes. Pharmacy Today, 2018, 24, 50-64.	0.0	2
31	Endocrine pharmacotherapy education in United States colleges and schools of pharmacy. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 481-489.	0.5	0
32	Part I: PSAP Live: Optimizing care in type 2 diabetes: Evidenceâ€based treatment design and therapy intensification. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 765-768.	0.5	0